Preparation of betaine injection and its therapeutic effect in pulmonary arterial hypertension
© 2023 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society). Published by John Wiley & Sons Ltd..
Pulmonary arterial hypertension (PAH) is a life-threatening disease characterised by elevated pulmonary pressure, right ventricular failure (RVF) and ultimately death. Aggressive treatment of RVF is considered an important therapeutic strategy to treat PAH. Previous studies have indicated that betaine may be may a promising therapeutic approach for PAH-induced RVF. Therefore, in this study, betaine solution for injection was prepared and characterised using various techniques. The therapeutic efficacy of three different methods of administration (intragastric, nebulised inhalation and intravenous injection) were comprehensively evaluated in terms of pharmacokinetics, tissue distribution and pharmacodynamics. The pharmacokinetic results demonstrated that betaine injection administered via nebulised inhalation significantly prolonged betaine's half-life and increased its internal circulation time compared to the intragastric and intravenous routes. Biodistribution experiments verified that the betaine formulation accumulated in the lung tissue when administered via inhalation. The results of the pharmacodynamic analysis further confirmed that right ventricular systolic pressure, mean pulmonary artery pressure and right ventricular hypertrophy index increased in the model group and that inhaled betaine suppressed these pathological changes to a level comparable to those observed in the control group. Taken together, these results indicate that betaine administered by inhalation is a promising strategy for the treatment of PAH-induced RVF.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:134 |
|---|---|
| Enthalten in: |
Basic & clinical pharmacology & toxicology - 134(2024), 2 vom: 27. Jan., Seite 219-230 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Che, Youlan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3SCV180C9W |
|---|
| Anmerkungen: |
Date Completed 12.01.2024 Date Revised 12.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bcpt.13966 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365007838 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365007838 | ||
| 003 | DE-627 | ||
| 005 | 20240114234307.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bcpt.13966 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1257.xml |
| 035 | |a (DE-627)NLM365007838 | ||
| 035 | |a (NLM)38009574 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Che, Youlan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Preparation of betaine injection and its therapeutic effect in pulmonary arterial hypertension |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.01.2024 | ||
| 500 | |a Date Revised 12.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society). Published by John Wiley & Sons Ltd. | ||
| 520 | |a Pulmonary arterial hypertension (PAH) is a life-threatening disease characterised by elevated pulmonary pressure, right ventricular failure (RVF) and ultimately death. Aggressive treatment of RVF is considered an important therapeutic strategy to treat PAH. Previous studies have indicated that betaine may be may a promising therapeutic approach for PAH-induced RVF. Therefore, in this study, betaine solution for injection was prepared and characterised using various techniques. The therapeutic efficacy of three different methods of administration (intragastric, nebulised inhalation and intravenous injection) were comprehensively evaluated in terms of pharmacokinetics, tissue distribution and pharmacodynamics. The pharmacokinetic results demonstrated that betaine injection administered via nebulised inhalation significantly prolonged betaine's half-life and increased its internal circulation time compared to the intragastric and intravenous routes. Biodistribution experiments verified that the betaine formulation accumulated in the lung tissue when administered via inhalation. The results of the pharmacodynamic analysis further confirmed that right ventricular systolic pressure, mean pulmonary artery pressure and right ventricular hypertrophy index increased in the model group and that inhaled betaine suppressed these pathological changes to a level comparable to those observed in the control group. Taken together, these results indicate that betaine administered by inhalation is a promising strategy for the treatment of PAH-induced RVF | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a aerosol inhale | |
| 650 | 4 | |a betaine | |
| 650 | 4 | |a injection | |
| 650 | 4 | |a pulmonary arterial hypertension | |
| 650 | 4 | |a right ventricular failure | |
| 650 | 7 | |a Betaine |2 NLM | |
| 650 | 7 | |a 3SCV180C9W |2 NLM | |
| 700 | 1 | |a Xia, Tian |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Cong |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Siyun |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Qingbin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Ru |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Basic & clinical pharmacology & toxicology |d 2004 |g 134(2024), 2 vom: 27. Jan., Seite 219-230 |w (DE-627)NLM144330768 |x 1742-7843 |7 nnns |
| 773 | 1 | 8 | |g volume:134 |g year:2024 |g number:2 |g day:27 |g month:01 |g pages:219-230 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bcpt.13966 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 134 |j 2024 |e 2 |b 27 |c 01 |h 219-230 | ||